Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403803 · ClinicalTrials.gov registry record
Prognosis and Therapeutic Biomarkers for Glioblastoma Patients
A clinical trial, sponsored by Baylor Research Institute.
- Terminated
- Registry status
- 10
- Enrollment target
NCT03403803: Clinical Trial study, sponsored by Baylor Research Institute.
NCT03403803 is a clinical trial that was terminated before completion, run by Baylor Research Institute. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03403803 was terminated before completion, sponsored by Baylor Research Institute.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
Primary Outcome
Currently, Glioblastoma is only diagnosed and monitored with brain scans. Expression levels of CD44 along with CD133, ABCC3, TNFRSF1A, AKT1, IDH2 and MGMT in samples of CSF, blood and saliva from patients receiving different types of treatment and comparing them with non-GBM patients (control group) will be tested.
Interventions
- DEVICE Optune
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2019-03-25 |
Why NCT03403803 stopped before completion
NCT03403803 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Optune is the first listed.
NCT03403803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03403803 about?
NCT03403803 is a clinical study titled "Prognosis and Therapeutic Biomarkers for Glioblastoma Patients". The purpose of this study is to investigate if the potential biomarkers identified could be used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
What is the current status of trial NCT03403803?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2017-09-01. Estimated completion is 2019-03-25.
What interventions are being tested in trial NCT03403803?
The interventions under investigation include: Optune (DEVICE).
Who is sponsoring clinical trial NCT03403803?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI